Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 Apr 2018
At a glance
- Drugs Nintedanib (Primary) ; Pirfenidone
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 11 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 22 Aug 2017 Status changed from not yet recruiting to recruiting.
- 10 Aug 2017 New trial record